Early Detection of Type 1 Diabetes in Pediatric Populations

Learning Objectives

• Recognize the stages of T1D progression and the benefits of early detection in pediatric populations
• Identify pediatric candidates for islet autoantibody (IAb) screening, including both high-risk and general populations
• Outline the process for IAb screening and subsequent management based on results

Download

Summary

T1D is a chronic, progressive autoimmune disease attacking insulin-producing beta-cells. Its progression is categorized into stages, with early detection of pre-clinical stages (Stages 1-2) in pediatric populations offering significant advantages. 

Early detection facilitates the development of glycemic management skills, reduces diabetic ketoacidosis, provides opportunities for clinical trials or treatment to delay onset, and allows for crucial education and counseling for families. Screening recommendations include high-risk populations (siblings of T1D patients, children with other autoimmune diseases) and the general population, starting as early as 2-4 years old. The screening process involves taking a blood sample for islet IAb testing, with clear pathways for follow-up based on the results, including referral to endocrinology teams for confirmed cases.

MAT-GLB-2601897 - 1.0 - 05/2026